Released: June 11, 2020

Defense Health Program
Department of Defense Combat Readiness-Medical Research Program
Anticipated Funding Opportunities for Fiscal Year 2020 (FY20)

The FY20 Defense Appropriations Act provides funding to the Department of Defense Combat Readiness – Medical Research Program (CRRP) to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service members in current and future battlefield settings. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Broad Agency Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 Congressional language for the CRRP considered research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma. The CRRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 Funding Opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 CRRP Broad Agency Announcement and General Submission Instructions for the following award mechanism will be posted on the website. Pre-application and application deadlines will be available when the Broad Agency Announcement is released. 

The FY20 CRRP will solicit research applications addressing at least one of the Focus Areas described below. The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.

Applications submitted to the FY20 CRRP must address at least one of the following Focus Areas:

  • Multiple-use scalable wound-care solutions that can address prevention of bleeding and infection, delivery of therapeutics, and promotion of healing spanning acute through chronic care
  • Repair and/or restoration of combat-related genitourinary organ and tissue damage
  • Solutions for assessment of mild traumatic brain injury in deployed and far-forward settings to include portable devices
  • Research and development of freeze-dried plasma and platelets to address hemorrhage and resuscitation
  • Solutions to enhance Warfighter readiness in battlefield and austere environments including the prevention and treatment of:
    • Gastrointestinal illness such as Enterotoxigenic Escherichia coli diarrheal disease and inflammatory bowel disease
    • Sleep disorders
    • Myalgic encephalomyelitis/chronic fatigue syndrome
    • Infectious diseases
  • Enhanced delivery and utilization of telemedicine platforms
Award Mechanism Eligibility Key Mechanism Elements Funding
Rapid Development and Translational Research Award
  • Extramural applicants only.
  • Independent investigators at all academic levels (or equivalent).
  • Submission of a preproposal is required; application submission is by invitation only.
  • Supports research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.
  • Preclinical research, including animal studies, that is already supported by substantial preliminary or published data and strongly validates clinical translation is appropriate.
  • Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed.
  • Maximum funding of $2,000,000 for total costs (to include direct and indirect costs).
  • Maximum period of performance is 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Broad Agency Announcement and General Submission Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Broad Agency Announcement is released. For email notification when Broad Agency Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at For more information about the CRRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Thursday, May 26, 2022